Liver Guidance

The BSG/BASL NAFLD special interest group have developed a series of evidence based quality standard recommendations, with the aim of improving the care of people with NAFLD. It is known that NAFLD is common, affecting 25% of the UK population […]

Wilson’s disease is an autosomal-recessive disorder of copper metabolism with hepatic, neurological, psychiatric, ophthalmological, haematological, renal, and rheumatological manifestations. Making a diagnosis can be challenging given that no single test can confirm or exclude the disease, and diagnostic delays are […]

Quality and Productivity: Proven Case Study Alcohol care teams: reducing acute hospital admissions and improving quality of care Provided by: The British Society of Gastroenterology and Bolton NHS Foundation Trust Publication type: Quality and productivity example Sharing good practice: What […]

Executive Summary Alcohol misuse and alcohol‐related problems, especially binge drinking and alcohol-related liver disease, are major public health concerns. Recently, much attention has focused on social policy and measures to reduce drinking. There is an additional need to provide care […]

Dear Liver Section members, I am writing to inform you of a significant caution about the use of ulipristal acetate (Esmya). Esmya is indicated for the pre-operative and intermittent treatment of moderate to severe symptoms of uterine fibroids in women […]

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

These recommendations were developed at a consensus meeting of clinicians and interested parties on 5 January 2016. Therapies that are NICE approved are presented in bold and those that are NICE unapproved are italicised. The prices of the different regimens […]

NICE technology appraisal guidance [TA364] Published date: November 2015

NICE technology appraisal guidance [TA365] Published date: November 2015